ArticleCell death & disease2025
Degradation of IRF6 by TRIM59 in tumor cells triggers PGM1-mediated glycolysis to regulate cell proliferation in neuroblastoma.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- TRIM59 Drives Bladder Cancer Progression Through E3 Ligase-Dependent K48-Linked Degradation of PTRF.Cancer science · 2026Article
- Systems-level analysis identifies IRF6 as an inhibitor of epithelial-mesenchymal transition.Journal of biological engineering · 2026Article
- Article
- Bulk and single cell RNA sequencing data reveal lactylation-related gene signatures for prognosis and immunity in cervical cancer.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Article
- TRIM59 promotes immune evasion and tumor progression in lung adenocarcinoma via ubiquitin- proteasomal degradation of IRF3.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Neuroblastoma is the most common extracranial malignancy in children, and patients who develop recurrent or metastatic disease are likely to have a much poorer survival prognosis. Herein, by applying random forest and XGBoost machine-learning techniques, we identified interferon regulatory factor (IRF) 6 as the most crucial gene associated with neuroblastoma patient survival. Low IRF6 expression was further determined to be associated with dismal survival in neuroblastoma patients. IRF6 overexpression inhibited cell proliferation in vitro and in vivo and even weakened glycolytic metabolism and increased maximal respiration in SK-N-BE2 and CHP-212 cells. Mechanistically, RNA sequencing, ChIP, and dual-luciferase reporter assays revealed that IRF6 inhibited PGM1 expression by decreasing the transcriptional activity of promoter 3 of PGM1, and PGM1 overexpression may reverse the inhibitory effects of IRF6 on cell proliferation and glycolysis. Additionally, IRF6 expression was diminished in neuroblastoma due to E3 ligase TRIM59-mediated polyubiquitination, and may reverse the promoting effect of TRIM59 overexpression on cell proliferation and glycolysis. Our work thus provides mechanistic insight into the control of glycolysis-mediated disease progression and opens new avenues for developing therapeutic strategies in neuroblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.